Garmin Ltd. vs McKesson Corporation — how do they compare? Garmin Ltd. trades at $271.28 (market cap $51.77B), while McKesson Corporation trades at $930 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 2.1× Garmin Ltd.'s market cap, and Garmin Ltd. pays the higher dividend (1.56%). Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and McKesson Corporation for 74 Days on average.
| GRMN | MCK | |
|---|---|---|
Market Cap | $51.77B | $108.46B |
Volume | 961,398 | 712,607 |
Sector | Technology | Health |
52-Week High | $313.16 | $995.69 |
52-Week Low | $187.10 | $725.17 |
Typical Hold Time | 83 Days | 74 Days |
Enterprise Value | $49.28B | $115.00B |
Dividend Yield | 1.56% | 0.4% |
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $276.16, down 1.09% today, showing strong fundamentals with consistent earnings beats and robust profitability. The company maintains impressive gross margins of 60.08% and net income margins of 24.47%, supported by steady revenue growth from $4.9B in 2022 to $7.25B in 2025. Recent positive developments include multiple product awards and new feature rollouts across marine, fitness, and automotive segments, though technical indicators suggest near-term bearish pressure.
Garmin presents a compelling investment case with strong financial performance and analyst consensus target of $320.25 (16% upside). However, elevated valuation ratios (P/E 28.5, P/S 6.97) and technical bearish signals warrant caution. Key risks include competitive pressures in wearable technology and potential economic sensitivity in consumer discretionary spending.
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →